407 related articles for article (PubMed ID: 26231497)
1. The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach.
Polcwiartek C; Sneider B; Graff C; Taylor D; Meyer J; Kanters JK; Nielsen J
Psychopharmacology (Berl); 2015 Sep; 232(18):3297-308. PubMed ID: 26231497
[TBL] [Abstract][Full Text] [Related]
2. Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.
Haddad PM; Anderson IM
Drugs; 2002; 62(11):1649-71. PubMed ID: 12109926
[TBL] [Abstract][Full Text] [Related]
3. QTc prolongation, torsades de pointes, and psychotropic medications.
Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
[TBL] [Abstract][Full Text] [Related]
4. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.
Glassman AH; Bigger JT
Am J Psychiatry; 2001 Nov; 158(11):1774-82. PubMed ID: 11691681
[TBL] [Abstract][Full Text] [Related]
5. QTc interval prolongation and torsade de pointes associated with second-generation antipsychotics and antidepressants: a comprehensive review.
Hasnain M; Vieweg WV
CNS Drugs; 2014 Oct; 28(10):887-920. PubMed ID: 25168784
[TBL] [Abstract][Full Text] [Related]
6. Assessing QT interval prolongation and its associated risks with antipsychotics.
Nielsen J; Graff C; Kanters JK; Toft E; Taylor D; Meyer JM
CNS Drugs; 2011 Jun; 25(6):473-90. PubMed ID: 21649448
[TBL] [Abstract][Full Text] [Related]
7. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly.
Vieweg WV; Wood MA; Fernandez A; Beatty-Brooks M; Hasnain M; Pandurangi AK
Drugs Aging; 2009; 26(12):997-1012. PubMed ID: 19929028
[TBL] [Abstract][Full Text] [Related]
8. The variant hERG/R148W associated with LQTS is a mutation that reduces current density on co-expression with the WT.
Mechakra A; Vincent Y; Chevalier P; Millat G; Ficker E; Jastrzebski M; Poulin H; Pouliot V; Chahine M; Christé G
Gene; 2014 Feb; 536(2):348-56. PubMed ID: 24334129
[TBL] [Abstract][Full Text] [Related]
9. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
[TBL] [Abstract][Full Text] [Related]
10. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.
Vieweg WV; Hasnain M; Hancox JC; Baranchuk A; Digby GC; Kogut C; Crouse EL; Koneru JN; Deshmukh A; Pandurangi AK
Psychopharmacology (Berl); 2013 Aug; 228(4):515-24. PubMed ID: 23812796
[TBL] [Abstract][Full Text] [Related]
11. Obstructive Sleep Apnea in Patients with Congenital Long QT Syndrome: Implications for Increased Risk of Sudden Cardiac Death.
Shamsuzzaman AS; Somers VK; Knilans TK; Ackerman MJ; Wang Y; Amin RS
Sleep; 2015 Jul; 38(7):1113-9. PubMed ID: 26118557
[TBL] [Abstract][Full Text] [Related]
12. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium.
Vandael E; Vandenberk B; Vandenberghe J; Spriet I; Willems R; Foulon V
Int J Clin Pharm; 2016 Apr; 38(2):310-20. PubMed ID: 26749342
[TBL] [Abstract][Full Text] [Related]
13. Ziprasidone in the management of schizophrenia : the QT interval issue in context.
Taylor D
CNS Drugs; 2003; 17(6):423-30. PubMed ID: 12697001
[TBL] [Abstract][Full Text] [Related]
14. Domperidone safety: a mini-review of the science of QT prolongation and clinical implications of recent global regulatory recommendations.
Buffery PJ; Strother RM
N Z Med J; 2015 Jun; 128(1416):66-74. PubMed ID: 26117678
[TBL] [Abstract][Full Text] [Related]
15. Drug-induced QT Interval Prolongation in the Intensive Care Unit.
Etchegoyen CV; Keller GA; Mrad S; Cheng S; Di Girolamo G
Curr Clin Pharmacol; 2017; 12(4):210-222. PubMed ID: 29473523
[TBL] [Abstract][Full Text] [Related]
16. Examination of baseline risk factors for QTc interval prolongation in patients prescribed intravenous haloperidol.
Muzyk AJ; Rayfield A; Revollo JY; Heinz H; Gagliardi JP
Drug Saf; 2012 Jul; 35(7):547-53. PubMed ID: 22702639
[TBL] [Abstract][Full Text] [Related]
17. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
18. Development of cardiac safety translational tools for QT prolongation and torsade de pointes.
Valerio LG; Balakrishnan S; Fiszman ML; Kozeli D; Li M; Moghaddam S; Sadrieh N
Expert Opin Drug Metab Toxicol; 2013 Jul; 9(7):801-15. PubMed ID: 23537164
[TBL] [Abstract][Full Text] [Related]
19. Schizophrenia, antipsychotic drugs, and cardiovascular disease.
Glassman AH
J Clin Psychiatry; 2005; 66 Suppl 6():5-10. PubMed ID: 16107178
[TBL] [Abstract][Full Text] [Related]
20. Clinical characteristics of patients with drug-induced QT interval prolongation and torsade de pointes: identification of risk factors.
Letsas KP; Efremidis M; Kounas SP; Pappas LK; Gavrielatos G; Alexanian IP; Dimopoulos NP; Filippatos GS; Sideris A; Kardaras F
Clin Res Cardiol; 2009 Apr; 98(4):208-12. PubMed ID: 19031039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
